AstraZeneca: Renal Insufficiency trials

The registry lists 29 Renal Insufficiency studies with AstraZeneca as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 26Phase 2 1Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedCompletedNCT03550378Phase 2Results posted
• A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal ImpairmentCompletedNCT00999336Phase 1Results posted
• Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal ImpairmentCompletedNCT00614939Phase 3Results posted
• AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)CompletedNCT00240331Phase 3Results posted
• Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinCompletedNCT07754331Phase 1
• Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)CompletedNCT07154901Phase 1
• Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234CompletedNCT06845813Phase 1
• A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004CompletedNCT06742762Phase 1
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy ParticipantsCompletedNCT06693765Phase 1
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal ImpairmentCompletedNCT06661733Phase 1
• A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal ImpairmentTerminatedNCT06639087Phase 1
• AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal ImpairmentTerminatedNCT06611423Phase 1
• A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780CompletedNCT06592482Phase 1
• A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal ImpairmentCompletedNCT05112419Phase 1
• To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.TerminatedNCT05065463Phase 1
• A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy VolunteersCompletedNCT04949438Phase 1
• Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney DysfunctionCompletedNCT04935294Phase 1
• Study of ALXN2050 in Participants With Renal ImpairmentCompletedNCT04623710Phase 1
• Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal ImpairmentCompletedNCT04469907Phase 1
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment SubjectsCompletedNCT03235375Phase 1
• Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1
• To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy SubjectsCompletedNCT02063204Phase 1
• Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal FunctionCompletedNCT01372826Phase 1
• A Study of Fostamatinib in Subjects With Impaired Kidney FunctionCompletedNCT01245790Phase 1
• To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal FunctionCompletedNCT01240967Phase 1
• Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal ImpairmentTerminatedNCT00984113Phase 1
• Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy VolunteersCompletedNCT00733265Phase 1
• Safety Study of AZD5672 in Renally Impaired SubjectsCompletedNCT00715702Phase 1
• Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered ConcomitantlyCompletedNCT00585143Phase 1